NASDAQ:CLCD - CoLucid Pharmaceuticals Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average Volume708,479 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
CoLucid Pharmaceuticals, Inc is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:CLCD
CUSIPN/A
Phone+1-781-3652596

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive CLCD News and Ratings via Email

Sign-up to receive the latest news and ratings for CLCD and its competitors with MarketBeat's FREE daily newsletter.


CoLucid Pharmaceuticals (NASDAQ:CLCD) Frequently Asked Questions

What is CoLucid Pharmaceuticals' stock symbol?

CoLucid Pharmaceuticals trades on the NASDAQ under the ticker symbol "CLCD."

How were CoLucid Pharmaceuticals' earnings last quarter?

CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) posted its earnings results on Wednesday, November, 9th. The biopharmaceutical company reported ($0.79) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.79). View CoLucid Pharmaceuticals' Earnings History.

Has CoLucid Pharmaceuticals been receiving favorable news coverage?

Media coverage about CLCD stock has trended somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. CoLucid Pharmaceuticals earned a coverage optimism score of 0.8 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for CoLucid Pharmaceuticals.

What other stocks do shareholders of CoLucid Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CoLucid Pharmaceuticals investors own include Gilead Sciences (GILD), Kite Pharma (KITE), Dova Pharmaceuticals (DOVA), Opko Health (OPK), Novavax (NVAX), Square (SQ), Ariad Pharmaceuticals (ARIA), Biostar Pharmaceuticals (BSPM), Celldex Therapeutics (CLDX) and Cyberark Software (CYBR).

When did CoLucid Pharmaceuticals IPO?

(CLCD) raised $55 million in an initial public offering on Wednesday, May 6th 2015. The company issued 5,500,000 shares at a price of $10.00 per share. Piper Jaffray and Stifel acted as the underwriters for the IPO and William Blair was co-manager.

What is CoLucid Pharmaceuticals' official website?

The official website for CoLucid Pharmaceuticals is http://www.colucid.com/.

How can I contact CoLucid Pharmaceuticals?

CoLucid Pharmaceuticals' mailing address is 222 3rd St, CAMBRIDGE, MA 02142-1102, United States. The biopharmaceutical company can be reached via phone at +1-781-3652596.


MarketBeat Community Rating for CoLucid Pharmaceuticals (NASDAQ CLCD)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  153 (Vote Outperform)
Underperform Votes:  180 (Vote Underperform)
Total Votes:  333
MarketBeat's community ratings are surveys of what our community members think about CoLucid Pharmaceuticals and other stocks. Vote "Outperform" if you believe CLCD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLCD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel